Insider filing · ZYME

EcoR1 Capital, LLC bought $1.4M of Zymeworks (ZYME)

Executed Apr 1 2025, disclosed Apr 2 2025, 1 day later.

Over the 21 trading sessions from the disclosed entry session (Apr 2 2025), the stock returned +9.8% (delay-adjusted); from the execution session (Apr 1 2025), +10.2%. Derived: entry at the session's open, exit at the close 20 sessions later.

EL EcoR1 Capital, LLC Director profile →

EcoR1 Capital, LLC (Director) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in ZYME. Across 2 priced purchase filings, the average 21-session return was +2.8% from execution and -5.0% from disclosure (delay-adjusted; derived). The largest single filing was $40.0M of AKTS (2,222,222 sh across 2 lots, as filed), executed Jan 12.

ZYME ZYME ZYME · 25 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→